UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 184

Sortiert nach

A QSAR study that compares the ability of bisdioxopiperazine analogs of the doxorubicin cardioprotective agent dexrazoxane (ICRF-187) to protect myocytes with DNA topoisomerase II inhibition

Toxicology and applied pharmacology, 2020-07, Vol.399, p.115038, Article 115038

2020

Volltextzugriff (PDF)

Progress curve analysis of the kinetics of slow-binding anticancer drug inhibitors of the 20S proteasome

Archives of biochemistry and biophysics, 2018-02, Vol.639, p.52-58

Hasinoff, Brian B.

2018

Volltextzugriff (PDF)

Molecular Mechanisms of the Cardiotoxicity of the Proteasomal-Targeted Drugs Bortezomib and Carfilzomib

Cardiovascular toxicology, 2017-07, Vol.17 (3), p.237-250

2017

Volltextzugriff (PDF)

The cardiotoxicity and myocyte damage caused by small molecule anticancer tyrosine kinase inhibitors is correlated with lack of target specificity

Toxicology and applied pharmacology, 2010-04, Vol.244 (2), p.190-195

Hasinoff, Brian B.

2010

Volltextzugriff (PDF)

The lack of target specificity of small molecule anticancer kinase inhibitors is correlated with their ability to damage myocytes in vitro

Toxicology and applied pharmacology, 2010-12, Vol.249 (2), p.132-139

2010

Volltextzugriff (PDF)

Disulfiram is a slow-binding partial noncompetitive inhibitor of 20S proteasome activity

Archives of biochemistry and biophysics, 2017-11, Vol.633, p.23-28

2017

Volltextzugriff (PDF)

Mechanisms of the Cardiac Myocyte-Damaging Effects of Dasatinib

Cardiovascular toxicology, 2020-08, Vol.20 (4), p.380-389

2020

Volltextzugriff (PDF)

The Role of Topoisomerase IIβ in the Mechanisms of Action of the Doxorubicin Cardioprotective Agent Dexrazoxane

Cardiovascular toxicology, 2020-06, Vol.20 (3), p.312-320

2020

Volltextzugriff (PDF)

Mechanisms of Action and Reduced Cardiotoxicity of Pixantrone; a Topoisomerase II Targeting Agent with Cellular Selectivity for the Topoisomerase IIα Isoform

The Journal of pharmacology and experimental therapeutics, 2016-02, Vol.356 (2), p.397

2016

Volltextzugriff (PDF)

The cytotoxicity of the anticancer drug elesclomol is due to oxidative stress indirectly mediated through its complex with Cu(II)

Journal of inorganic biochemistry, 2014-08, Vol.137, p.22-30

2014

Volltextzugriff (PDF)

Myocyte-Damaging Effects and Binding Kinetics of Boronic Acid and Epoxyketone Proteasomal-Targeted Drugs

Cardiovascular toxicology, 2018-12, Vol.18 (6), p.557-568

2018

Volltextzugriff (PDF)

The Myocyte-Damaging Effects of the BCR-ABL1-Targeted Tyrosine Kinase Inhibitors Increase with Potency and Decrease with Specificity

Cardiovascular toxicology, 2017-07, Vol.17 (3), p.297-306

2017

Volltextzugriff (PDF)

Molecular mechanisms of the biological activity of the anticancer drug elesclomol and its complexes with Cu(II), Ni(II) and Pt(II)

Journal of inorganic biochemistry, 2013-09, Vol.126, p.1-6

2013

Volltextzugriff (PDF)

Mechanisms of Myocyte Cytotoxicity Induced by the Multiple Receptor Tyrosine Kinase Inhibitor Sunitinib

Molecular pharmacology, 2008-12, Vol.74 (6), p.1722-1728

2008

Volltextzugriff (PDF)

Abstract 3060: Molecular mechanisms of the cardiotoxicity of the proteasomal-targeted anticancer drugs bortezomib and carfilzomib

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.3060-3060

2016

Volltextzugriff (PDF)

Evaluation of Nitrobenzyl Derivatives of Camptothecin as Anti-Cancer Agents and Potential Hypoxia Targeting Prodrugs

Molecules (Basel, Switzerland), 2018-08, Vol.23 (8), p.2041

2018

Volltextzugriff (PDF)

Cellular mechanisms of the cytotoxicity of the anticancer drug elesclomol and its complex with Cu(II)

Biochemical pharmacology, 2015-02, Vol.93 (3), p.266-276

2015

Volltextzugriff (PDF)

The anticancer multi-kinase inhibitor dovitinib also targets topoisomerase I and topoisomerase II

Biochemical pharmacology, 2012-12, Vol.84 (12), p.1617-1626

2012

Volltextzugriff (PDF)

The use of dexrazoxane for the prevention of anthracycline extravasation injury

Expert opinion on investigational drugs, 2008-02, Vol.17 (2), p.217-223

Hasinoff, Brian B

2008

Volltextzugriff (PDF)

The anticancer thiosemicarbazones Dp44mT and triapine lack inhibitory effects as catalytic inhibitors or poisons of DNA topoisomerase IIα

Biochemical pharmacology, 2012-07, Vol.84 (1), p.52-58

2012

Volltextzugriff (PDF)

Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy

Toxicology (Amsterdam), 2009-01, Vol.255 (1), p.72-79

2009

Volltextzugriff (PDF)

Structure-based design, synthesis and biological testing of etoposide analog epipodophyllotoxin–N-mustard hybrid compounds designed to covalently bind to topoisomerase II and DNA

Bioorganic & medicinal chemistry, 2014-11, Vol.22 (21), p.5935-5949

2014

Volltextzugriff (PDF)

Expression of a stress‐induced hemoglobin affects NO levels produced by alfalfa root cultures under hypoxic stress

The Plant journal : for cell and molecular biology, 2003-09, Vol.35 (6), p.763-770

2003

Volltextzugriff (PDF)

Class-1 hemoglobins, nitrate and NO levels in anoxic maize cell-suspension cultures

Planta, 2004-05, Vol.219 (1), p.66-72

2004

Volltextzugriff (PDF)

Mechanisms of Myocyte Cytotoxicity Induced by the Multikinase Inhibitor Sorafenib

Cardiovascular toxicology, 2010-03, Vol.10 (1), p.1-8

2010

Volltextzugriff (PDF)

1 – 25 von 184

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(176)
Mit Volltextzugriff
(171)

Publikationsform

Artikel
(184)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(137)
Life Sciences & Biomedicine
(131)
Animals
(71)
Pharmacology & Pharmacy
(62)
Biological And Medical Sciences
(57)
Biochemistry & Molecular Biology
(54)
Humans
(48)
Medical Sciences
(44)
Chemistry
(40)
Physical Sciences
(39)
Rats
(36)
Pharmacology. Drug Treatments
(33)
Doxorubicin
(31)
Dexrazoxane
(30)
Rats, Sprague-Dawley
(30)
Kinetics
(29)
K562 Cells
(27)
Antineoplastic Agents - Pharmacology
(26)
Razoxane - Pharmacology
(26)
Topoisomerase Ii Inhibitors
(23)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

A QSAR study that compares the ability of bisdioxopiperazine analogs of the doxorubicin cardioprotective agent dexrazoxane (ICRF-187) to protect myocytes with DNA topoisomerase II inhibition

Progress curve analysis of the kinetics of slow-binding anticancer drug inhibitors of the 20S proteasome

Molecular Mechanisms of the Cardiotoxicity of the Proteasomal-Targeted Drugs Bortezomib and Carfilzomib

The cardiotoxicity and myocyte damage caused by small molecule anticancer tyrosine kinase inhibitors is correlated with lack of target specificity

The lack of target specificity of small molecule anticancer kinase inhibitors is correlated with their ability to damage myocytes in vitro

Disulfiram is a slow-binding partial noncompetitive inhibitor of 20S proteasome activity

Mechanisms of the Cardiac Myocyte-Damaging Effects of Dasatinib

The Role of Topoisomerase IIβ in the Mechanisms of Action of the Doxorubicin Cardioprotective Agent Dexrazoxane

Mechanisms of Action and Reduced Cardiotoxicity of Pixantrone; a Topoisomerase II Targeting Agent with Cellular Selectivity for the Topoisomerase IIα Isoform

The cytotoxicity of the anticancer drug elesclomol is due to oxidative stress indirectly mediated through its complex with Cu(II)

Myocyte-Damaging Effects and Binding Kinetics of Boronic Acid and Epoxyketone Proteasomal-Targeted Drugs

The Myocyte-Damaging Effects of the BCR-ABL1-Targeted Tyrosine Kinase Inhibitors Increase with Potency and Decrease with Specificity

Molecular mechanisms of the biological activity of the anticancer drug elesclomol and its complexes with Cu(II), Ni(II) and Pt(II)

Mechanisms of Myocyte Cytotoxicity Induced by the Multiple Receptor Tyrosine Kinase Inhibitor Sunitinib

Abstract 3060: Molecular mechanisms of the cardiotoxicity of the proteasomal-targeted anticancer drugs bortezomib and carfilzomib

Evaluation of Nitrobenzyl Derivatives of Camptothecin as Anti-Cancer Agents and Potential Hypoxia Targeting Prodrugs

Cellular mechanisms of the cytotoxicity of the anticancer drug elesclomol and its complex with Cu(II)

The anticancer multi-kinase inhibitor dovitinib also targets topoisomerase I and topoisomerase II

The use of dexrazoxane for the prevention of anthracycline extravasation injury

The anticancer thiosemicarbazones Dp44mT and triapine lack inhibitory effects as catalytic inhibitors or poisons of DNA topoisomerase IIα

Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy

Structure-based design, synthesis and biological testing of etoposide analog epipodophyllotoxin–N-mustard hybrid compounds designed to covalently bind to topoisomerase II and DNA

Expression of a stress‐induced hemoglobin affects NO levels produced by alfalfa root cultures under hypoxic stress

Class-1 hemoglobins, nitrate and NO levels in anoxic maize cell-suspension cultures

Mechanisms of Myocyte Cytotoxicity Induced by the Multikinase Inhibitor Sorafenib

Suchergebnisse filtern